Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Prediction of metabolic clearance in extreme individuals rather than the 'average human' is becoming an attractive tool within the pharmaceutical industry. The current study involved prediction of variability in metabolic clearance for alprazolam, triazolam and midazolam with emphasis on the following factors: first, evaluation of clearance prediction accuracy using intrinsic clearance (CL(int)) data from in vitro metabolic data and back-calculation from in vivo clearance data. Second, the sensitivity of predicted in vivo variability to changes in variability for physiological parameters (e.g. liver weight, haematocrit, CYP3A abundance). Finally, reported estimates of variability in hepatic CYP3A4 abundance (coefficient of variation (CV) 95%) were refined by separating experimental from interindividual variability using a repeat measurement protocol in 52 human liver samples. Using in vitro metabolic data, predicted clearances were within 2-fold of observed for triazolam and midazolam. Clearance of alprazolam was overpredicted by 2.0- to 3.7-fold. Use of in vivo CL(int) values improved prediction of intravenous clearance to within 2-fold of observed for all drugs. Initially, the variability in clearance was overestimated for all drugs (by 1.8- to 3.6-fold). Use of a reduced hepatic CYP3A4 CV of 41%, representative of interindividual variability alone improved predictions of variability in clearance for all drugs to within 2-fold of observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 8×
“Of the four CYP3A genes identified in human, significant concentrations of protein have been found for CYP3A4 and CYP3A5 (Shimada et al., 1994; Paine et al., 1997; Hustert et al., 2001; Kuehl et al., 2001).”
BackgroundInfluentialObach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Self-citationComparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Barter, Z., Bayliss, M., Beaune, P., Boobis, A., Carlile, D., Edwards, R., Brian Houston, J., Lake, B., Lipscomb, J., Pelkonen, O., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315053 · Cited by 459
Self-citationWestlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683197 · Cited by 223 · cited 14×
“…)G gut gut gut G,int (20) Total blood clearances after oral and intravenous administration were calculated using individual organ clearances and associated availabilities (Howgate et al., 2006; Jamei et al., 2009, Equations 21 and 22 and Figure 1): CL =CL CLiv H r (21) CL = CL CL fa F Fpo H r H G”
BackgroundMethodResultSelf-citationThe Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam
Abernethy, D. R., Greenblatt, D. J., Divoll, M., Smith, R. B., & Shader, R. I. (1984) · Clinical Pharmacokinetics · doi:10.2165/00003088-198409020-00005 · Cited by 99 · cited 2×
“Simulations were run in order to mimic one intravenous and one oral study for each compound (Fleishaker et al., 1989; Ciraulo et al., 1988 for alprazolam, Derry et al., 1995; Abernethy et al., 1984 for triazolam and Eeckhoudt et al., 2001; Backman et al., 1995 for midazolam).”
MethodSmith, R. B., & Kroboth, P. D. (1987) · Psychopharmacology · doi:10.1007/bf02439595 · Cited by 76
Cited by
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Almond, L. M., Mukadam, S., Gardner, I., Okialda, K., Wong, S., Hatley, O., Tay, S., Rowland-Yeo, K., Jamei, M., Rostami-Hodjegan, A., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066845 · Cited by 101
Self-citationHeikkinen, A. T., Baneyx, G., Caruso, A., & Parrott, N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.013 · Cited by 76
Poulin, P., & Haddad, S. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23502 · Cited by 54
T’jollyn, H., Boussery, K., Mortishire-Smith, R. J., Coe, K., De Boeck, B., Van Bocxlaer, J. F., & Mannens, G. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039982 · Cited by 48
Metadata
- Authors
- Cubitt, H. E., Yeo, K. R., Howgate, E. M., Rostami-Hodjegan, A., & Barter, Z. E.
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 2011-03-24
- Volume
- 41
- Issue
- 8
- Pages
- 623-638
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W2062891364
- Cited by
- 56
- References
- 10
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. https://app.cochat.ai/papers/10.3109/00498254.2011.560294
- The paper
- Cubitt, H. E., Yeo, K. R., Howgate, E. M., Rostami-Hodjegan, A., & Barter, Z. E. (2011). Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica. https://doi.org/10.3109/00498254.2011.560294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.